Leerink Downgrades Orexigen, Cuts Target From $4.50 To $2
February 23, 2016 at 09:35 AM EST
Leerink’s Paul Matteis downgraded the rating for Orexigen Therapeutics, Inc. (NASDAQ: OREX) from Outperform to Market Perform, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.